Design Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Design Therapeutics

08/11/2022 03:39

* Design Therapeutics Inc  DSGN.OQ  reported a quarterly
adjusted
loss of 32 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 29 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Design Therapeutics Inc's reported EPS for the quarter was
a
loss of 32 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Design Therapeutics Inc shares had fallen by 7.5% this
quarter and lost 27.8% so far this year.
    * The company reported a quarterly loss of $17.7 million.
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $29.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 03:39 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.29          -0.32          Missed
 Jun. 30 2022      -0.25          -0.27          Missed
 Mar. 31 2022      -0.22          -0.24          Missed
 Dec. 31 2021      -0.23          -0.20          Beat